arrow
S

Steven Knapper

Cardiff University
H指数:37
被引数:5,681

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Co-administration of the long-acting monoclonal antibody AZD7442 and bivalent Ancestral/BA.1 vaccination is well-tolerated in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus: the results of the multicentre, open-label, phase II randomised controlled, RAPID-PROTECTION trial

长效单克隆抗体AZD7442与双价祖先/BA.1疫苗接种联合给药在高度易感SARS-CoV-2病毒感染的免疫抑制患者中耐受性良好:多中心、开放标签、II期随机对照RAPID-PROTECTION试验的结果

2026-11-130
OAAI
The leukaemia in pregnancy study, a national multicentre retrospective study of pregnancy outcomes in women with concurrent or historic diagnoses of acute leukaemia

妊娠期白血病研究,一项关于同时或既往被诊断患有急性白血病的女性妊娠结局的国家多中心回顾性研究

2026-10-160
OAAI
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

将奎沙替尼与强化化疗联合应用于新诊断AML的老年患者:英国NCRI AML18试验结果

Blood
IF23.1
2026-06-250
OA
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom

英国大型多中心队列分析揭示加速期和原始细胞期骨髓增殖性肿瘤的治疗模式与结局

2026-05-030
OAAI
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial

CPX-351与柔红霉素、阿糖胞苷联合吉姆单抗奥佐米星在非不良风险AML老年患者中的比较:NCRI AML18试验

Blood
IF23.1
2025-11-180
PRE
Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML.

联合中剂量阿糖胞苷和吉妥单抗奥佐米星与诱导化疗在FLT3突变急性髓系白血病中的安全性和有效性。

2025-10-030
OAAI
A revised prognostic model for patients with acute myeloid leukemia and first relapse

针对急性髓系白血病首次复发的修订型预后模型

2025-05-260
OA
Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

非COVID感染在AML/MDS治疗患者中的前瞻性队列研究:对实践的启示

BLOOD
IF23.1
2024-11-050
PRE
Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 'Midotarg Pilot'

基于Gemtuzumab的诱导化疗与Midostaurin联合用于FLT3突变患者的治疗。结果来自NCRI AML19V2 'Midotarg Pilot'研究中的患者报告结局测量数据。

BLOOD
IF23.1
2024-11-050
PRE
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

RUX-AZA对AP/BP-MPN的响应由突变HSPCs的分化阻滞释放驱动:一项对Phazar Ib期研究中响应者的单细胞多组学分析

BLOOD
IF23.1
2024-11-050
PRE
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
2023-11-253
OAAI
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

针对TIM-3抗体的新型免疫疗法sabatolimab (MBG453) 与地西他滨或阿扎胞苷联合治疗高危或极高危骨髓增生异常综合征的Ib期研究

2023-11-2212
OAAI
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
2023-08-1114
OAAI
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
LEUKEMIA
IF13.4
2023-08-0920
OAAI
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
2023-06-055
OAAI
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
2022-11-143
OAAI